First-line pembrolizumab plus chemotherapy versus chemotherapy in advanced esophageal cancer: Longer-term efficacy, safety, and quality-oflife results from the phase 3 KEYNOTE-590 study

Jean-Philippe Metges; Ken Kato; Jong-Mu Sun; Manish A. Shah; Peter C. Enzinger; Antoine Adenis; Toshihiko Doi; Takashi Kojima; Zhigang Li; Sung-Bae Kim; Byoung Chul Cho; Wasat Mansoor; Shau-Hsuan Li; Patrapim Sunpaweravong; MARIA ALSINA; Gary L Buchschacher; Jimin Wu; Sukrut Shah; Pooja Bhagia; Lin Shen

doi:10.1200/JCO.2022.40.4_suppl.241

YUHSpace

BROWSE

0 138

Cited 0 times in

First-line pembrolizumab plus chemotherapy versus chemotherapy in advanced esophageal cancer: Longer-term efficacy, safety, and quality-oflife results from the phase 3 KEYNOTE-590 study

Authors: Jean-Philippe Metges ; Ken Kato ; Jong-Mu Sun ; Manish A. Shah ; Peter C. Enzinger ; Antoine Adenis ; Toshihiko Doi ; Takashi Kojima ; Zhigang Li ; Sung-Bae Kim ; Byoung Chul Cho ; Wasat Mansoor ; Shau-Hsuan Li ; Patrapim Sunpaweravong ; MARIA ALSINA ; Gary L Buchschacher ; Jimin Wu ; Sukrut Shah ; Pooja Bhagia ; Lin Shen